Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Drug Injury
  • About Our Firm
  • Free Case Evaluation
  • Frequently Asked Questions

Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma

August 11, 2021 By Law Offices of Thomas J. Lamb, P.A.

Objectives: Second-line immune checkpoint inhibition (ICI) was recently shown to have a survival advantage over placebo in malignant pleural mesothelioma (MPM), but the survival comparison to chemotherapy in patients with MPM receiving routine clinical care is unknown. Our objective was to examine the effectiveness of second-line ICI versus … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, pleural mesothelioma

Neoadjuvant pemetrexed plus cisplatin followed by pleurectomy for malignant pleural mesothelioma.

August 5, 2021 By Law Offices of Thomas J. Lamb, P.A.

PURPOSE: Despite becoming the preferred surgical technique for malignant pleural mesothelioma, pleurectomy/decortication has received few prospective clinical trials. Therefore, the Japan Mesothelioma Interest Group conducted a prospective multi-institutional study to evaluate the feasibility of neoadjuvant chemotherapy followed by … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma treatments, pleural mesothelioma, pleurectomy

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma

March 31, 2021 By Law Offices of Thomas J. Lamb, P.A.

AbstractMalignant mesothelioma (MM) is a treatment-resistant tumor originating in the mesothelial lining of the pleura or the abdominal cavity with very limited treatment options. More effective therapeutic approaches are urgently needed to improve the poor prognosis of MM patients. Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, pericardial mesothelioma, peritoneal mesothelioma, pleural mesothelioma

New Options Spark Sequencing and Biomarker Trials in Mesothelioma

February 11, 2021 By Law Offices of Thomas J. Lamb, P.A.

Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual patients [ with unresectable pleural mesothelioma ], … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos, asbestos cancer, mesothelioma, mesothelioma treatments, pleural mesothelioma

Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup

September 1, 2020 By Law Offices of Thomas J. Lamb, P.A.

Purpose: Human malignant pleural mesothelioma (MPM) is characterized by dismal prognosis. Consequently, dissection of molecular mechanisms driving malignancy is of key importance. Here we investigate, whether activating mutations in the telomerase reverse transcriptase (TERT) gene promoter are present in [malignant pleural mesothelioma (MPM)] and … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, pleural mesothelioma

Malignant Diffuse Mesothelioma in Women โ€” A Study of 354 Cases

February 11, 2020 By Law Offices of Thomas J. Lamb, P.A.

We reviewed 354 cases of malignant diffuse mesothelioma (MM) in women from a database of 2858 histologically confirmed MM cases. There was a pleural predominance with 78% [ pleural malignant mesothelioma ] and 22% [ peritoneal malignant mesothelioma ]. The pleural tumors consisted of 72% epithelioid, 19% biphasic, and 9% sarcomatoid variant. The … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos cancer, asbestos exposure, mesothelioma, peritoneal mesothelioma, pleural mesothelioma

50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience

December 27, 2019 By Law Offices of Thomas J. Lamb, P.A.

Background:  The most common sites of malignant mesothelioma are the pleura and peritoneum, but little is known about the incidence, prognosis, or treatment of patients with disease in both cavities. Previous series suggest that multimodality treatment improves overall survival for pleural or peritoneal disease, but studies typically exclude [ … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, peritoneal mesothelioma, pleural mesothelioma

Radical hemithoracic radiotherapy doubles survival among certain patients with mesothelioma

December 3, 2019 By Law Offices of Thomas J. Lamb, P.A.

Patients with malignant pleural mesothelioma who underwent nonradical surgery and chemotherapy appeared twice as likely to achieve 2-year OS with radical hemithoracic radiotherapy vs. palliative radiotherapy, according to randomized phase 3 study results presented at European Society for Radiotherapy and Oncology Congress. Based on these … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, pleural mesothelioma

Diagnostic Value of Biopsy Sampling in Predicting Histology in Patients With Diffuse Malignant Pleural Mesothelioma

August 15, 2019 By Law Offices of Thomas J. Lamb, P.A.

BACKGROUND: The classification of diffuse malignant mesothelioma into epithelioid, biphasic, and sarcomatoid types is based on histologic patterns. The diagnosis is made on biopsies, and because of intratumoral heterogeneity, they may not be representative of the entire tumor. The number and volume of biopsies needed to reach diagnostic accuracy in … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma diagnosis, pleural mesothelioma

Another Antiangiogenic Failure in Unresectable Mesothelioma

June 20, 2019 By Law Offices of Thomas J. Lamb, P.A.

The addition of nintedanib (Ofev) to standard of care pemetrexed (Alimta) plus cisplatin failed to delay disease progression in patients with unresectable malignant pleural mesothelioma, according to phase III results of the LUME-Meso study. After a median treatment duration of more than 5 months, median progression-free survival was 6.8 months … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, pleural mesothelioma

  • 1
  • 2
  • 3
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form โ€“ it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Cases
  • Breast Implant Cases
  • Philips Breathing Devices Cases
  • GenX Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2022 ยท Law Offices of Thomas J. Lamb, P.A.